KAG-308

EP4-selective agonist shows efficacy for treating ulcerative colitis and can bring about lower risk of colorectal carcinogenesis; structure in first source

Also Known As:

3,3-difluorohexahydro-4-((1E,3R,4R)-3-hydroxyl-4-(3-methylphenyl)-1-penten-1-yl)-2-(4-(1H-tetrazol-5-yl)butylidene)-2H-cyclopenta(b)furan-5-ol

Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Amakawa, Masahiro: 2 articles (12/2019 - 05/2015)
2.	Miyake, Yoshihide: 2 articles (12/2019 - 05/2015)
3.	Chijimatsu, Ryota: 1 article (12/2019)
4.	Iba, Kousuke: 1 article (12/2019)
5.	Maenohara, Yuji: 1 article (12/2019)
6.	Murahashi, Yasutaka: 1 article (12/2019)
7.	Nakamoto, Hideki: 1 article (12/2019)
8.	Saito, Taku: 1 article (12/2019)
9.	Tanaka, Sakae: 1 article (12/2019)
10.	Yamanaka, Hiroyuki: 1 article (12/2019)

Related Diseases

1.	Carcinogenesis 05/05/2015 - "KAG-308 also prevented colorectal carcinogenesis by inhibiting colitis development and consequently decreasing mortality in a CAC model, whereas SASP had marginal effects. " 05/05/2015 - "KAG-308, a newly-identified EP4-selective agonist shows efficacy for treating ulcerative colitis and can bring about lower risk of colorectal carcinogenesis by oral administration."
2.	Ulcerative Colitis 05/05/2015 - "KAG-308, a newly-identified EP4-selective agonist shows efficacy for treating ulcerative colitis and can bring about lower risk of colorectal carcinogenesis by oral administration."
3.	Knee Osteoarthritis 12/30/2019 - "Oral administration of EP4-selective agonist KAG-308 suppresses mouse knee osteoarthritis development through reduction of chondrocyte hypertrophy and TNF secretion."
4.	Synovitis 12/30/2019 - "Cartilage degeneration and synovitis were significantly inhibited by the KAG-308 treatment. " 12/30/2019 - "Thus, we conclude that oral administration of KAG-308 suppresses OA development through suppression of chondrocyte hypertrophy and synovitis. "
5.	Hypertrophy 12/30/2019 - "Thus, we conclude that oral administration of KAG-308 suppresses OA development through suppression of chondrocyte hypertrophy and synovitis. " 12/30/2019 - "Oral administration of EP4-selective agonist KAG-308 suppresses mouse knee osteoarthritis development through reduction of chondrocyte hypertrophy and TNF secretion."

Related Drugs and Biologics

1.	Dextran Sulfate
2.	Sulfasalazine (Azulfidine)

Related Therapies and Procedures

1.	Oral Administration